Disease/Infection News

RSS

Studies reveal impact and spread of CVBDs worldwide

Fascinating studies giving new insights into the spread of leishmaniosis in the UK and France, the appearance of new CVBDs in Germany, the state of heartworm infection in Korea and the neurological impact on humans of long-term bartonella infection from the USA are among the papers now available for download from http://www.cvbd.org, as the proceedings of the 5th Annual Canine Vector Borne Disease (CVBD) World Forum are made available online today.

28 Jul 2010

Taiwanese hemophiliacs infected by HIV-contaminated medications petition US Supreme Court

Baum Hedlund announces that Taiwanese hemophiliacs infected by HIV-contaminated medications have petitioned the United States Supreme Court to allow their claims to proceed in California. Their suits contend that California-based defendants illegally used paid plasma donors at high risk for transmitting blood-borne diseases (i.v. drug users, prisoners, and promiscuous urban gay males) to make injected anti-hemophilia medications.

28 Jul 2010

New funding made available to tackle common cause of food poisoning in the UK

Up to £2 Million is being made available today to tackle the most common cause of food poisoning in the UK - Campylobacter. Three of the UK's main public funders of food safety research have come together to invite research proposals to find out more about the organism and how best to control it. To provide safe and nutritious food for a growing world population it is important to reduce the incidence of food poisoning. Campylobacter species are responsible for more than 300,000 cases of food poisoning a year in England and Wales.

28 Jul 2010

BiondVax receives 2010 European Influenza Vaccines Technology Innovation Award

Frost & Sullivan is pleased to announce the award of its prestigious 2010 European Influenza Vaccines Technology Innovation Award to BiondVax Pharmaceuticals for their breakthrough work on a universal influenza vaccine. This vaccine, the Multimeric-001, is designed to provide multi-season and multi-strain protection against most influenza virus strains, including both seasonal and pandemic strains, and has the potential to eliminate the need for annual flu vaccination. BiondVax is entering Phase II clinical trials for the development of the Multimeric-001 universal influenza vaccine.

28 Jul 2010

Dengue fever emerges as major health threat in Gulf coast cities

Several cases of dengue fever, a potentially fatal viral disease transmitted by the bite of urban dwelling Aedes aegypti and Aedes albopictus mosquitoes, have recently been reported in the continental United States. Prevalent in Central America and the Caribbean, dengue fever's most common symptoms include fever, chills, headache, and body aches lasting several days. The disease's more threatening form, dengue hemorrhagic fever, can cause internal bleeding, loss of blood pressure, and death. Over the past five years, outbreaks of both forms of the disease have been reported in Texas and Florida.

28 Jul 2010

Merck, Sinopharm sign statement of mutual intent for cooperation on HPV vaccine

Merck, known outside the U.S. and Canada as MSD, and Sinopharm today announced the signing of a statement of mutual intent. Under the statement, Sinopharm and Merck will cooperate on HPV vaccine and other mutually-selected vaccine products in China, and will also discuss the potential for promoting and marketing Merck's pharmaceutical products in China.

28 Jul 2010

NIH awards Akonni $435K to develop point-of-care diagnostics for multi-drug resistant strains of MTB

Akonni Biosystems a molecular diagnostics company focused on developing and manufacturing rapid, high multiplex solutions for infectious disease testing, today announced receipt of a $435K grant from the National Institutes of Biomedical Imaging and Bioengineering at the National Institutes of Health. The award will enable Akonni to accelerate development of its hands-free, sample-to-answer system for identifying a broader range of multi-drug resistant strains of Mycobacterium tuberculosis.

28 Jul 2010

DIATHERIX Laboratories opens rapid response diagnostic panels for STD, HSV

DIATHERIX Laboratories ,adds a Sexually Transmitted Disease (STD) panel and Herpes Simplex Virus (HSV) panel to its line up of highly sensitive, rapid response diagnostic panels. The HSV panel identifies herpes simplex viruses 1 and 2 and the STD panel identifies 10 sexually transmitted diseases simultaneously, many of which cannot be accurately identified by current testing methods. These STD organisms, if not appropriately treated, can cause diseases such as syphilis, gonorrhoeae, chlamydia, bacterial vaginosis, etc. and may lead to blindness, infertility or complications during pregnancy.

28 Jul 2010

35 cases of hepatitis C among Melbourne abortion clinic patients

Over the last few months there has been a rise in hepatitis C cases at an abortion clinic in Melbourne. In a new development 13 new cases have been diagnosed. This brings the total count to 35. The Victorian police are investigating the source of the infections. The link between the Croydon Day Surgery and the cluster was first revealed in April, when there were only 12 cases.

28 Jul 2010

Antigenics announces positive results of AG-707 genital herpes vaccine

Antigenics announced positive results with AG-707, an investigational therapeutic vaccine being developed to treat herpes simplex virus-2,the virus that causes genital herpes, in infected patients. Developed by Antigenics, the vaccine triggers a cellular immune response, stimulating both CD4+ and CD8+ T cells.

28 Jul 2010

Haiti: might the earthquake worsen TB rates?

Prior to the earthquake of January 12th 2010, Haiti had experienced the highest TB notification rate in the Latin America and Caribbean region. In a forthcoming editorial in Expert Review of Respiratory Medicine, Kevin Schwartzman and colleagues from the McGill University Health Centre (Montreal, Canada) discuss whether the devastation of Haiti six months ago will lead to an unavoidable increase in the incidence of TB.

27 Jul 2010

NPMA releases results of 2010 Comprehensive Global Bed Bug Study

A new survey conducted by the National Pest Management Association and the University of Kentucky, confirms what pest management professionals across the U.S. and around the world have been seeing in the field - bed bugs are back in a very big way, with 95 percent of U.S. survey respondents indicating that their company has encountered a bed bug infestation in the past year. Prior to 2000, only 25 percent of U.S. survey respondents encountered a bed bug infestation.

27 Jul 2010

Singapore hepatitis C therapeutics market revenue to increase to $4.5 billion by 2017

The Singaporean government's emphasis on raising awareness on the benefit of frequent health check-ups have significantly raised the number of Hepatitis C Virus (HCV) diagnosed cases in the country, expanding the patient pool. Therapeutics companies have a challenging task ahead for improving treatment for this market as current treatment requires high dosage frequency, but potentially has serious side effects.

27 Jul 2010

Neurodegenerative disease-causing infectious protein can erupt from healthy brain tissue: Study

In a startling new study that involved research on both sides of the Atlantic, scientists from The Scripps Research Institute in Florida and the University College London Institute of Neurology in England have shown for the first time that abnormal prions, bits of infectious protein devoid of DNA or RNA that can cause fatal neurodegenerative disease, can suddenly erupt from healthy brain tissue.

27 Jul 2010

EFINTD awards 850,000 Euros for medical research on neglected tropical diseases in Africa

More than one billion people all over the world suffer from tropical diseases which are mostly unknown to the wider public and have also been neglected economically. In a joint effort with four other European foundations, the Volkswagen Foundation has opened a second round of funding for African scientists conducting research on these neglected diseases.

27 Jul 2010

Female sexual dysfunction can affect quality of life: Research

Almost two-thirds of females attending a general urology practice reported that they suffered from sexual dysfunction, according to a paper in the August issue of BJUI. Dysfunction rose with age in all categories except orgasm, with more than half of women aged from 18 to 30 reporting orgasm problems, significantly higher than women aged 31 to 54.

27 Jul 2010

Advanced Life Sciences enters agreement with UBC to develop antimicrobial peptides

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced that the Company has entered into a sponsored research and option agreement with The University of British Columbia (UBC) to develop several antimicrobial peptides.

27 Jul 2010

Global Fund director calls on emerging countries to invest more in programs to reduce HIV/AIDS, TB and malaria at AIDS 2010

On the final day of the International AIDS Conference-AIDS 2010 Friday, Michel Kazatchkine, executive director of the Global Fund to Fight AIDS, Tuberculosis and Malaria called upon "China, India and other fast-growing economies" to chip in to help close the funding gap in efforts to battle HIV/AIDS, Agence France-Presse reports. "Until now, these countries have been recipients of AIDS funds, not donors," the news service writes.

27 Jul 2010

Albert Einstein College of Medicine receives research grant to help people with MDR-TB

For the third time in four months, the National Institute of Allergy and Infectious Diseases of the National Institutes of Health has awarded Albert Einstein College of Medicine of Yeshiva University a research grant aimed at helping people infected with multidrug-resistant tuberculosis. Taken together, all three NIH grants total $8.57 million.

27 Jul 2010

Study on interactions between new antitubercular drug candidates SQ109 and TMC207

Sequella, Inc., a clinical-stage biopharmaceutical company developing drugs for treatment of life-threatening infectious diseases, announced today the publication of studies in the scientific journal Antimicrobial Agents and Chemotherapy on synergy between SQ109, its lead drug candidate for the treatment of TB, and TMC207, Tibotec lead TB drug candidate:

27 Jul 2010

Disease/Infection News

Studies reveal impact and spread of CVBDs worldwide

Taiwanese hemophiliacs infected by HIV-contaminated medications petition US Supreme Court

New funding made available to tackle common cause of food poisoning in the UK

BiondVax receives 2010 European Influenza Vaccines Technology Innovation Award

Dengue fever emerges as major health threat in Gulf coast cities

Merck, Sinopharm sign statement of mutual intent for cooperation on HPV vaccine

NIH awards Akonni $435K to develop point-of-care diagnostics for multi-drug resistant strains of MTB

DIATHERIX Laboratories opens rapid response diagnostic panels for STD, HSV

35 cases of hepatitis C among Melbourne abortion clinic patients

Antigenics announces positive results of AG-707 genital herpes vaccine

Haiti: might the earthquake worsen TB rates?

NPMA releases results of 2010 Comprehensive Global Bed Bug Study

Singapore hepatitis C therapeutics market revenue to increase to $4.5 billion by 2017

Neurodegenerative disease-causing infectious protein can erupt from healthy brain tissue: Study

EFINTD awards 850,000 Euros for medical research on neglected tropical diseases in Africa

Female sexual dysfunction can affect quality of life: Research

Advanced Life Sciences enters agreement with UBC to develop antimicrobial peptides

Global Fund director calls on emerging countries to invest more in programs to reduce HIV/AIDS, TB and malaria at AIDS 2010

Albert Einstein College of Medicine receives research grant to help people with MDR-TB

Study on interactions between new antitubercular drug candidates SQ109 and TMC207

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News